Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination

11Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause. We report a 67-year-old man with Pityriasis rubra pilaris might induced by COVID-19 vaccination. The patient developed the lesions after the first dose of vaccine and significantly aggravated after the second dose. He had poor effect and liver function impairment developed after acitretin used, but achieved satisfactory efficacy after replacement to ixekizumab, an interleukin-17A inhibitor.

Cite

CITATION STYLE

APA

Liu, Y. ting, & Wang, S. shang. (2023). Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination. Skin Health and Disease, 3(1). https://doi.org/10.1002/ski2.139

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free